echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Deqi Pharmaceutical ATG-101 was certified as an orphan drug by the US FDA

    Deqi Pharmaceutical ATG-101 was certified as an orphan drug by the US FDA

    • Last Update: 2022-10-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 19, 2022, Beijing time, Deqi Pharmaceutical Co.


    Deqi Pharmaceutical's first new PD-L1/4-1BB bispecific antibody ATG-101 independently developed by Deqi Pharma has been certified as an orphan drug by the US Food and Drug Administration (FDA) for the treatment of pancreatic cancer

    There is currently no approved PD-L1/4-1BB bispecific antibody


    Orphan drug, also known as rare disease drugs, refers to drugs used to prevent, treat and diagnose rare diseases


    The FDA grants orphan drug designation to help develop drug candidates that may benefit patients with rare diseases in the U.


    ATG-101 is a novel PD-L1/4-1BB bispecific antibody that can block immunosuppressive PD-L1/PD-1 binding and conditionally activate 4-1BB co-stimulation signals, thereby activating anti-tumor immune effector cells and improving safety


    ATG-101 is a novel PD-L1/4-1BB bispecific antibody that can block immunosuppressive PD-L1/PD-1 binding and conditionally activate 4-1BB co-stimulation signals, thereby activating anti-tumor immune effector cells and improving safety


    Dr.


    About Deqi MedicineDeqi Medicine doctors have no boundaries, innovation and sustainability

    Since 2017, Deqi Pharma has now established an expanding pipeline of 15 clinical and preclinical products, of which 10 products have global interests and 5 products have Asia-Pacific interests


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.